Chemistry:Foretinib
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
N1-[3-Fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N′1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
| Other names
XL880; EXEL-2880; GSK1363089; GSK089
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C34H34F2N4O6 | |
| Molar mass | 632.665 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tracking categories (test):
Foretinib is an experimental drug candidate for the treatment of cancer.[1] It was discovered by Exelixis and is under development by GlaxoSmithKline.[2] About 10 Phase II clinical trials have been run.[3] (As of October 2015) it appears development has been discontinued.[4]
Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).[5]
See also
- c-Met inhibitors
- Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
- VEGFR inhibitor
- tyrosine-kinase inhibitor
References
- ↑ Hedgethorne, K.; Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs of the Future 35 (11): 893–901. doi:10.1358/dof.2010.35.11.1529012.
- ↑ "XL880 (GSK1363089)". Exelixis, Inc. http://www.exelixis.com/pipeline/xl880.
- ↑ "Foretinib". clinicaltrials.gov. http://clinicaltrials.gov/ct2/results?term=Foretinib+.
- ↑ "Foretinib - AdisInsight". http://adisinsight.springer.com/drugs/800022245.
- ↑ Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer Research 69 (20): 8009–16. doi:10.1158/0008-5472.CAN-08-4889. PMID 19808973.
 |  |
